Thirty-six HIV-infected patients with chronic hepatitis C treated with peginterferon alpha-2a or 2b plus ribavirin were analysed in a prospective observational study. There were 15 (42%) treatment discontinuations; by intent-to-treat virological responders were 19 (53%) at week 24. A higher fibrosis score predicted premature discontinuation of hepatitis C virus (HCV) therapy and a lack of early virological response. Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals.
|Number of pages||3|
|Journal||AIDS (London, England)|
|Publication status||Published - Jul 23 2004|
ASJC Scopus subject areas
- Immunology and Allergy